SYNTHESIS OF N-ALKYL-1,2,4-OXADIAZINONES AS ANGIOTENSIN-II (AT1) RECEPTOR ANTAGONISTS


The Bristol-Myers Squibb Pharmaceutical Research Institute
P.O. Box 4000, Princeton, NJ 08543-4000 U.S.A.

Abstract- 4-Alkyl-1,2,4-oxadiazinones were prepared by regiospecific alkylation of the corresponding 4H-oxadiazinones, which were synthesized by a trimethylaluminum mediated cyclization reaction. Alkylation was regiospecific and generally facile; in one example, however, an unusual fragmentation reaction occurred. A homochiral oxadiazinone was also prepared and alkylated under the described conditions. 4-Biphenylmethyl-1,2,4-oxadiazinones were potent angiotensin-II receptor antagonists.

In the course of our research into preparation of novel angiotensin-II receptor antagonists, we sought to identify bioisosteric heterocycles to replace the imidazole ring in prototype antagonists such as Exp-7711,1 DuP-753,1 and SKF 108,566.2 Alkyl-(4E)-1,2,4-oxadiazin-5-ones, exemplified by 1, appeared to be attractive targets and have not been previously reported in the literature. An obvious synthetic approach to such targets would be N-alkylation of the parent heterocycles. The literature states, however, that the 1,2,4-oxadiazinone ring "appears to have acidic properties but is resistant to alkylation or acylation",3 and even if alkylation were to be achieved questions of regiochemistry would remain to be addressed. We have overcome these difficulties and now report an improved synthesis of 4H-1,2,4-oxadiazinones and their regiospecific 4-alkylation, resulting in a series of novel and potent angiotensin-II receptor antagonists. In addition, we report synthesis of a homochiral 1,2,4-oxadiazinone.

Oxadiazinones have been prepared by reaction of amidoximes with α-halo acid chlorides4 or α-halo esters.5 In our hands, reaction of amidoxime (2) with α-bromooesters (3) led smoothly to the Q-alkyl ester intermediates (4),
but subsequent ring closure was often sluggish even at elevated temperatures. Addition of trimethylaluminum to the crude ester intermediate, however, led to rapid ring closure at room temperature. Thus, reaction of amidoxime (2) with \( \alpha \)-bromo esters (3) in dimethylformamide containing excess potassium or cesium carbonate, followed by treatment of the crude product mixture with trimethylaluminum in dichloromethane led to oxadiazinones (5a-e) in generally good yield (Table 1 and Scheme 1). Example (5d) gave a low yield due to competing elimination reactions leading to cinnamates. The homochiral example (5f) was prepared by reaction of 2 with ethyl 2-(R)-trifluoromethanesulfonyloxy-4-phenyl butyrate with presumed inversion. The enantiomer ratio of 5f was determined by chiral hplc to be greater than 96 to 4.

Reaction of oxadiazinones (5a-f) with biphenyl bromide (6) in the presence of potassium or cesium carbonate in dimethylformamide gave smooth alkylation, leading to products (7). Esters (7a, 7b, and 7d-f) were isolated as viscous oils, characterized spectroscopically, then converted directly to the desired carboxylic acids (8) by treatment with trifluoroacetic acid (Scheme 1). The acids were purified by preparative hplc, lyophilized, and obtained as hygroscopic solids. The enantiomer ratio determined by chiral phase hplc for 8f was the same as for 5f, thus epimerization of the chiral center does not occur during alkylation.

In the case of the phenyl substituted example (5e), fragmentation took place under alkylation conditions to give keto amide (9) as the only isolated product (75%). We initially assumed that fragmentation was due to the enhanced acidity of the \( \alpha \)-hydrogen atom in 7e resulting from stabilization of the corresponding anion by the adjacent phenyl ring. If this were so, then treatment of 7a, 7b, or 7d-f with stronger base should result in similar fragmentation. Treatment of 7e with lithium diisopropylamide at 25°C led to a highly colored species, but 7e was recovered intact after aqueous workup. Attempted alkylation (MeI) or deuteration (DCl/D\(_2\)O) of the presumed
anion failed. Treatment of 5c with cesium carbonate in dimethylformamide (e.g., in the absence of alkylating agent (6)) failed to give fragmentation, and the starting material was recovered intact. Further studies will be required to elucidate the scope and mechanism of this unusual fragmentation reaction.

**Table 1: Preparation and Alkylation of Oxadiazinones**

<table>
<thead>
<tr>
<th>Entry</th>
<th>X</th>
<th>R</th>
<th>R'</th>
<th>Yield of 5</th>
<th>Yield of 7</th>
<th>Yield of 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>a</td>
<td>Br</td>
<td>H</td>
<td>Methyl</td>
<td>71%</td>
<td>55%</td>
<td>60%</td>
</tr>
<tr>
<td>b</td>
<td>Br</td>
<td>Methyl</td>
<td>Ethyl</td>
<td>48%</td>
<td>78%</td>
<td>54%</td>
</tr>
<tr>
<td>c</td>
<td>Br</td>
<td>Phenyl</td>
<td>Methyl</td>
<td>64%</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>d</td>
<td>Br</td>
<td>Benzyl</td>
<td>Ethyl</td>
<td>20%</td>
<td>58%</td>
<td>86%</td>
</tr>
<tr>
<td>e</td>
<td>Br</td>
<td>(+/-)-Phenylethyl</td>
<td>Ethyl</td>
<td>57%</td>
<td>81%</td>
<td>81%</td>
</tr>
<tr>
<td>f</td>
<td>(R)-OSO₂CF₃</td>
<td>(S)-Phenylethyl</td>
<td>Ethyl</td>
<td>56%</td>
<td>68%</td>
<td>82%</td>
</tr>
</tbody>
</table>

The high yield obtained for 9 suggests that alkylation of 5c is predominantly at N₄ (rather than N₂) of the oxadiazinone. For the other examples (a, b, and d-f) a single N-alkyl regioisomer was obtained. Regiochemistry was proven for the series by unambiguous synthesis of 7a and 7e from the corresponding N-alkylamidoxime (12), prepared using known methodology¹¹ (Scheme 2). The final cyclization step (13 → 7) proceeds in poor yield for the N-alkyl derivatives (13), possibly due to a poor equilibrium population of N-alkylamidoxime regioisomers.
In the biphenylmethylimidazole series, replacement of the carboxylic acid group (e.g., EXP-7711) with a tetrazole group (e.g., DuP-753) leads to improved angiotensin II receptor affinity (Table 2). We thus prepared biphenylmethyltetrazole (16) by alkylation of 5e with biphenylmethyl nitrile (14), followed by conversion of the nitrile to tetrazole by reaction with tributyltin azide (Scheme 3).

Biphenylmethyl oxadiazinones were evaluated for binding to angiotensin II AT\(_1\) receptors from rat adrenal cortex (K\(_i\)) and for functional antagonism of angiotensin induced contraction of rabbit aorta (K\(_B\)). Results shown in Table 2 indicate that receptor affinity and functional antagonism increase with increased steric bulk of the 6-position substituent (R). Since the racemic phenylethyl analog (8e) and its homochiral counterpart (8f) do not have the same biological activity, we believe the effect of the substituent R to be the result of a specific receptor interaction.
rather than of lipophilicity alone. The most potent carboxylic acid analog (8e) displays receptor binding affinity and functional antagonism equal to or better than the prototype carboxylic acid EXP-7711. Replacement of the carboxylic acid group with the tetrazole group (16) leads to improvement in receptor affinity, but not in functional antagonism.

### Table 2: Biological Activity of Biphenylmethyl Oxadiazinones

<table>
<thead>
<tr>
<th>Compound</th>
<th>R</th>
<th>X</th>
<th>$K_1$ (nM)</th>
<th>$K_B$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8a</td>
<td>H</td>
<td>CO$_2$H</td>
<td>6,200 ± 1,200</td>
<td>290 ± 16</td>
</tr>
<tr>
<td>8b</td>
<td>Methyl</td>
<td>CO$_2$H</td>
<td>720 ± 120</td>
<td>220 ± 65</td>
</tr>
<tr>
<td>8d</td>
<td>Benzyl</td>
<td>CO$_2$H</td>
<td>790 ± 240</td>
<td>98 ± 42</td>
</tr>
<tr>
<td>8e</td>
<td>(+/-)-Phenylethyl</td>
<td>CO$_2$H</td>
<td>50 ± 9</td>
<td>27 ± 8</td>
</tr>
<tr>
<td>8f</td>
<td>(S)-Phenylethyl</td>
<td>CO$_2$H</td>
<td>420 ± 33</td>
<td>170 ± 31</td>
</tr>
<tr>
<td>16</td>
<td>(+/-)-Phenylethyl</td>
<td>tetrazole</td>
<td>16 ± 2.5</td>
<td>70 ± 3.4</td>
</tr>
<tr>
<td>EXP-7711</td>
<td>--</td>
<td>CO$_2$H</td>
<td>95 ± 15</td>
<td>86 ± 4.4</td>
</tr>
<tr>
<td>DuP 753</td>
<td>--</td>
<td>tetrazole</td>
<td>5.7 ± 0.6</td>
<td>2.6 ± 0.13</td>
</tr>
</tbody>
</table>

In conclusion, we have described an improved synthesis of oxadizinones and their regiospecific N-alkylation, leading to novel and potent angiotensin II (AT$_1$) antagonists.

### EXPERIMENTAL

**General.** All new compounds were homogeneous by thin layer chromatography and reversed-phase hplc. Except as noted, extracts were dried over magnesium sulfate prior to concentration. Flash chromatography was carried out on E. Merck Kieselgel 60 silica gel (240-400 mesh). $^1$H NMR and $^{13}$C NMR spectra were obtained on a JEOL CPF-270 spectrometer operating at 270 or 67.5 MHz, respectively, and are reported as ppm downfield from an internal tetramethylsilane standard. Melting points are uncorrected.
Radioligand binding studies were performed using rat adrenal cortical membranes prepared as described by Chiu et al. Binding experiments were performed essentially as described using [125I] Sar1Ile8 angiotensin-II as the radioligand. The BSA concentration was reduced in some cases to 0.01% to attenuate drug binding to BSA. Contractile responses in rabbit aorta were determined as described elsewhere.

**General Procedure for Preparation of Oxadiazinones.** 3-Butyl-4H-1,2,4-oxadiazin-5(6H)-one (5a). Methyl bromoacetate (1.42 ml, 15.0 mmol) was added to a mixture of amidoxime 2 (1.16 g, 10 mmol) and cesium carbonate (6.5 g, 20 mmol) in dimethylformamide (50 ml). The mixture was stirred at 25°C for 18 h, after which it was poured into water (300 ml), extracted with ethyl acetate (3 x 200 ml), dried, and concentrated in vacuo to provide crude (4a) as an amber oil. The oil was dissolved in dichloromethane (150 ml) under argon, and a solution of trimethylaluminium in hexane (25 ml of a 2.0 M solution, 50 mmol) was added. The resulting mixture was stirred for 6 h, after which it was poured into cold 0.5 N hydrochloric acid (300 ml), and extracted with dichloromethane (3 x 300 ml). The crude extract was purified using flash chromatography (200 g of silica gel eluted with 3:1 hexane:ethyl acetate); fractions containing the major product were combined and concentrated in vacuo. The residue was triturated with ether to give 5a as white shiny flakes, 1.11 g (71 %), mp 51-52°C; nmr (δ, ppm, CDC13): 0.85 (3H, t, J = 7 Hz, 1.30 (2H, m), 1.62 (2H, m), 2.40 (2H, t, J = 7 Hz), 4.30 (2H, s); 13C nmr (δ, ppm, CDC13): 13.0, 13.4, 21.7, 27.8, 30.0, 71.8, 152.9, 166.9; ms: (M+H)/z = 157. Anal. Calcd for C7H12N2O2: C, 56.45; H, 8.29; N, 16.46. Found: C, 56.54; H, 8.42; N, 16.31.

3-Butyl-4H-1,2,4-oxadiazin-5(6H)-one (5b). This compound was obtained as white flakes (48%), mp 80-81°C; nmr (δ, ppm, CDC13): 0.85 (3H, t, J = 7 Hz), 1.20 (2H, m), 1.55 (2H, m), 2.32 (2H, t, J = 7 Hz), 4.15 (1H, q, J = 7 Hz), 9.65 (1H, br s); 13C nmr (δ, ppm, CDC13): 13.0, 13.4, 21.7, 27.8, 30.0, 71.8, 152.9, 168.9; ms: (M+H)/z = 171. Anal. Calcd for C8H14N2O2: C, 56.45; H, 8.29; N, 16.46. Found: C, 56.54; H, 8.42; N, 16.31.

3-Butyl-6-methyl-4H-1,2,4-oxadiazin-5(6H)-one (5c). This compound was obtained as a white solid (64%), mp 67-68°C; nmr (δ, ppm, CDC13): 0.86 (3H, t, J = 7 Hz), 1.22 (2H, m), 1.55 (2H, m), 2.32 (2H, t, J = 7 Hz), 5.42 (1H, s), 7.4 (5H, m), 9.45 (1H, br s); 13C nmr (δ, ppm, CDC13): 13.5, 21.6, 27.7, 30.2, 77.6, 127.2, 128.5, 129.0, 132.6, 151.7, 167.1; ms: (M+H)/z = 233. Anal. Calcd for C13H16N2O2: C, 67.22; H, 6.94; N, 12.06. Found: C, 67.23; H, 6.84; N, 11.93.

3-Butyl-6-phenyl-4H-1,2,4-oxadiazin-5(6H)-one (5d). This compound was obtained from petroleum ether as a white solid (20%), mp 84-85°C; nmr (δ, ppm, CDC13): 0.86 (3H, t, J = 7 Hz), 1.35 (2H, m), 1.60 (2H, m), 2.32 (2H, t, J = 7 Hz), 3.18 (2H, dd, J = 3 and 7 Hz), 4.38 (1H, dd, J = 3 and 7 Hz), 7.3 (5H, m), 9.75 (1H, br s); 13C nmr (δ, ppm, CDC13): 13.4, 21.7, 27.6, 29.9, 33.8, 76.5, 126.6, 128.8, 129.1, 136.0, 152.7, 167.9; ms: (M+H)/z = 247. Anal. Calcd for C14H18N2O2: C, 68.27; H, 7.37; N, 11.37. Found: C, 68.12; H, 7.48; N, 11.28.

3-Butyl-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-5(6H)-one (5e). This compound was obtained from 5 petroleum ether: ether as a white solid (57%), mp 79-80°C; nmr (δ, ppm, CDC13): 0.95 (3H, t, J = 7 Hz), 1.40 (2H, m), 1.63 (2H, m), 2.20 (2H, m), 2.42 (2H, t, J = 7 Hz), 3.18 (2H, m), 4.18 (1H, dd, J = 3 and 7 Hz), 7.3 (5H, m), 9.75 (1H, br s); 13C nmr (δ, ppm, CDC13): 13.4,
(S)-3-Butyl-1-(2-phenylethyl)-4H-1,2,4-oxadiazin-5(6H)-one (5f). To a mixture of (R)-ethyl 2-hydroxy-4-phenyl butyrate (120 mg, 0.6 mmol) and pyridine (0.048 ml, 0.6 mmol) in dichloromethane (3 ml) at 0°C under argon was added tris(2,2,2-trifluoroethoxycarbonyl)amido anhydride (0.115 ml, 1.7 mmol). The resulting mixture was stirred at 0°C for 1 h, after which it was filtered through a small (7 ml) pad of silica gel and washed with dichloromethane. The filtrate was concentrated in vacuo to a volume of about 3 ml and was added to a solution of 2 (35 mg, 0.3 mmol) and triethylamine (0.08 ml, 0.6 mmol) in dichloromethane (2 ml). After 2 h, the mixture was poured into water (100 ml), extracted with dichloromethane (2 x 100 ml), dried, and concentrated in vacuo. The residue was dissolved in dichloromethane (5 ml); a solution of trimethylaluminum in hexanes (0.6 ml of 2 M solution, 1.2 mmol) was added, and the resulting mixture was stirred for 3 h. The mixture was then poured into 0.5 N hydrochloric acid (100 ml), extracted with dichloromethane (2 x 100 ml), dried, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (30 gm), eluting with 5:1 hexane : ethyl acetate, to give 5f as colorless plates (from ether), 44 mg, mp 105-106°C; nmr (δ, ppm, CDCl3): 0.95 (3H, t, J = 7 Hz), 1.40 (2H, m), 1.63 (2H, m), 2.20 (2H, m), 2.42 (2H, t, J = 7 Hz), 3.18 (2H, m), 4.18 (1H, dd, J = 3 and 7 Hz), 7.3 (5H, m), 9.75 (1H, br s); 13C nmr (δ, ppm, CDCl3): 13.4, 21.7, 27.6, 29.3, 30.0, 30.8, 74.2, 125.9, 128.3, 140.4, 152.8, 168.8; ms: (M+H)/z = 261.1603 (calcd for C15H21N2O2 = 261.1603). Anal. Calcd for C15H21N2O2: C, 75.26; H, 7.28; N, 5.19. Found: C, 75.34; H, 7.28; N, 5.19.

General procedure for alkylation of oxadiazinones. 4′-[(3-Butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl)methyl][1,1′-biphenyl]-2-carboxylic acid t-butyli ester (7e). A mixture of 5e (520 mg, 2.0 mmol), biphenyl bromide (6) (960 mg, 2.4 mmol),10 and cesium carbonate (1.30 g, 4.0 mmol) in dimethylformamide (10 ml) was stirred at 25°C for 19 h, after which it was poured into brine and extracted with ethyl acetate. The extract was dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (300 gm), eluting with 10:1 hexane : ethyl acetate, to give 7e as a viscous oil, 850 mg (81%). nmr (δ, ppm, CDCl3): 0.90 (3H, t, J = 7 Hz), 1.25 (9H, s), 1.40 (1H, m), 1.60 (1H, m), 2.20-2.50 (4H, m), 2.90 (2H, m), 4.19 (1H, dd, J = 3 and 7 Hz), 4.78 (1H, d, J = 14 Hz), 5.20 (1H, d, J = 14 Hz), 7.10-7.90 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.6, 22.1, 27.5, 28.2, 29.5, 30.9, 43.9, 75.0, 81.2, 126.0, 127.2, 128.4, 128.5, 129.2, 129.6, 130.4, 130.5, 130.6, 132.7, 134.8, 140.7, 141.2, 141.5, 154.7, 166.9, 167.8; ms: (M+H)/z = 527. Anal. Calcd for C33H30N2O4: C, 75.26; H, 7.27; N, 5.32. Found: C, 75.34; H, 7.28; N, 5.19.

4′-[(3-Butyl-5,6-dihydro-5-oxo-4H-1,2,4-oxadiazin-4-yl)methyl][1,1′-biphenyl]-2-carboxylic acid t-butyli ester (7a). This compound was obtained as a viscous oil (55%); nmr (δ, ppm, CDCl3): 0.89 (3H, t, J = 7 Hz), 1.22 (9H, s), 1.37 (2H, m), 1.59 (2H, m), 2.45 (2H, t, J = 7 Hz), 4.40 (2H, s), 5.00 (2H, s), 7.20-7.90 (8H, m); 13C nmr (δ, ppm, CDCl3): 13.5, 21.9, 27.4, 28.1, 29.4, 43.3, 67.1, 81.0, 125.9, 127.0, 129.0, 129.5, 130.2, 130.5, 132.6, 134.5, 141.0, 141.4, 154.7, 164.8, 167.5; ms: (M+H)/z = 423. Anal. Calcd for C25H30N2O4: 0.59 H2O: C, 69.33; H, 7.25; N, 6.47. Found: C, 69.41; H, 7.04; N, 6.39.
4'-[(3-Butyl-5,6-dihydro-6-methyl-5-oxo-4H-1,2,4-oxadiazin-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid t-butyl ester (7b). This compound was obtained as a viscous oil (78%); nmr (δ, ppm, CDCl3): 0.90 (3H, t, J = 7 Hz), 1.22 (9H, s), 1.37 (2H, m), 1.58 (3H, d, J = 7 Hz), 1.60 (2H, m), 2.40 (2H, t, J = 7 Hz), 4.25 (1H, q, J = 7 Hz), 4.85 (1H, d, J = 14 Hz), 5.27 (1H, d, J = 14 Hz), 7.20-7.90 (8H, m); 13C nmr (δ, ppm, CDCl3): 13.7, 22.1, 27.6, 28.4, 29.7, 44.1, 72.6, 81.3, 126.1, 127.3, 129.2, 129.7, 130.4, 130.7, 132.8, 134.9, 141.2, 141.3, 154.0, 167.5, 167.6; ms: (M+H)/z = 437.

4'-[(3-Butyl-5,6-dihydro-5-oxo-6-(phenylmethyl)-4H-1,2,4-oxadiazin-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid t-butyl ester (7d). This compound was obtained as a viscous oil (58%); nmr (δ, ppm, CDCl3): 0.79 (3H, t, J = 7 Hz), 1.10 (9H, s), 1.24 (2H, m), 1.43 (2H, m), 2.27 (2H, t, J = 7 Hz), 2.90 (1H, dd, J = 3 and 14 Hz), 3.25 (1H, dd, J = 3 and 14 Hz), 4.28 (1H, dd, J = 3 and 7 Hz), 4.60 (1H, d, J = 14 Hz), 5.10 (1H, d, J = 14 Hz), 7.00-7.72 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.9, 22.4, 27.9, 29.9, 34.6, 44.3, 77.2, 81.4, 126.4, 127.0, 127.5, 128.6, 129.1, 129.5, 129.9, 130.6, 131.0, 133.1, 135.1, 136.7, 141.5, 141.8, 154.8, 166.6, 168.0; ms: (M+H)/z = 513.

(S)-4'-[(3-Butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid (7f). This compound was obtained as a viscous oil (68%); nmr (δ, ppm, CDCl3): 0.90 (3H, t, J = 7 Hz), 1.25 (9H, s), 1.40 (1H, m), 1.60 (1H, m), 2.20-2.50 (4H, m), 2.90 (2H, m), 4.19 (1H, m), 4.78 (1H, d, J = 14 Hz), 5.20 (1H, d, J = 14 Hz), 7.10-7.90 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.6, 22.1, 27.5, 28.2, 29.5, 30.9, 43.9, 75.0, 81.2, 126.0, 127.2, 128.4, 128.5, 129.2, 129.6, 130.4, 130.5, 130.6, 130.8, 134.8, 140.7, 141.2, 141.5, 154.7, 166.9, 167.8; ms: (M+H)/z = 527.

General procedure for deprotection of t-butyI esters. 4'-[(3-Butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid (8e). To a solution of 7e (460 mg, 0.87 mmol) in dichloromethane (20 ml) was added trifluoroacetic acid (20 ml, 200 mmol), and the mixture was stirred at room temperature for 1.5 h. The solution was concentrated in vacuo and purified by preparative hplc on a YMC 30×500 mm S-10 ODS column, eluting with 50 ml/min of 78% aqueous methanol containing 0.1% trifluoroacetic acid. Fractions containing the major product were combined and concentrated and the residue was lyophilized from ethanol/water to provide 8e as a hygroscopic white solid, 335 mg (81%); mp 74-80°C; nmr (δ, ppm, CD3OD): 0.89 (3H, t, J = 7 Hz), 1.30 (2H, m), 1.52 (2H, m), 2.00-2.60 (4H, m), 2.82 (2H, m), 4.20 (1H, dd, J = 3 and 7 Hz), 4.84 (1H, d, J = 14 Hz), 5.20 (1H, d, J = 14 Hz), 7.10-7.90 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.5, 22.0, 28.3, 29.5, 29.7, 30.9, 44.1, 75.1, 125.9, 126.1, 127.3, 128.4, 128.8, 129.1, 130.7, 131.1, 132.1, 134.9, 140.6, 140.7, 142.6, 155.2, 167.0, 172.9; ms: (M+H)/z = 471.2301 (calcd for C29H31N2O4: 471.2284). Anal. Calcd for C29H30N2O4: 0.25 H2O: C, 73.32; H, 6.47; N, 5.90. Found: C, 73.32; H, 6.44; N, 5.75.

4'-[(3-Butyl-5,6-dihydro-5-oxo-4H-1,2,4-oxadiazin-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid (8a). This compound was obtained as a white solid (60%); mp 125-130°C; nmr (δ, ppm, CD3OD): 0.96 (3H, t, J = 7 Hz), 1.42 (2H, m), 1.61 (2H, m), 2.50 (2H, t, J = 7 Hz), 4.50 (2H, s), 5.18 (2H, s), 7.20-7.90 (8H, m); 13C nmr (δ, ppm, CD3OD): 14.2, 23.3, 29.6, 30.7, 44.9, 68.6, 127.6, 128.7, 130.5, 101.0, 132.1, 132.6, 133.2, 137.1, 142.6, 143.2, 157.3, 167.1, 172.4; ms: (M+H)/z = 367.1648 (calcd for C21H23N2O4: 367.1658). Anal. Calcd for C21H22N2O4: 1.0 H2O: C, 65.61; H, 6.29; N, 7.29. Found: C, 65.52; H, 6.00; N, 7.36.
4'-[(3-Butyl-5,6-dihydro-6-methyl-5-oxo-4H,1,2,4-oxadiazen-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid (8b). This compound was obtained as a white solid (54%); mp 64-66°C; nmr (δ, ppm, CD3OD): 0.80 (3H, t, J = 7 Hz), 1.25 (2H, m), 1.40 (3H, d, J = 7 Hz), 1.45 (2H, m), 2.39 (2H, m), 4.12 (1H, q, J = 7 Hz), 4.75 (1H, d, J = 14 Hz), 5.18 (1H, d, J = 14 Hz), 7.10-7.80 (8H, m); 13C nmr (δ, ppm, CD3OD): 13.9, 14.0, 23.0, 29.2, 30.4, 45.0, 73.6, 127.1, 128.3, 130.1, 130.7, 131.8, 132.2, 132.8, 136.7, 142.1, 142.8, 168.9, 172.0; ms: (M+H)/z = 457.2118 (calcd for C29H24N2O4: 457.2127). Anal. Calcd for C29H24N2O4: C, 71.85; H, 6.06; N, 6.02.

4'-[(3-Butyl-5,6-dihydro-5-oxo-6-(phenylmethyl)-4H,1,2,4-oxadiazen-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid (8c). This compound was obtained as a white solid (86%); mp 64-66°C; nmr (δ, ppm, CD3OD): 0.95 (3H, t, J = 7 Hz), 1.41 (2H, m), 1.60 (2H, m), 2.50 (2H, m), 3.17 (1H, dd, J = 7 and 14 Hz), 3.50 (1H, dd, J = 3 and 7 Hz), 4.56 (1H, dd, J = 3 and 7 Hz), 4.95 (1H, d, J = 14 Hz), 5.30 (1H, d, J = 14 Hz), 7.20-8.00 (13H, m); 13C nmr (δ, ppm, CD3OD): 14.0, 23.0, 29.2, 30.4, 35.2, 45.0, 78.1, 126.8, 127.7, 129.3, 130.6, 131.3, 132.2, 132.8, 133.6, 136.6, 137.8, 138.9, 143.2, 156.7, 167.8, 171.9; ms: (M-H)/z = 457.2118 (calcd for C29H29N2O4: 457.2127). Anal. Calcd for C29H29N2O4: 0.5 H2O: C, 72.24; H, 6.28; N, 6.02. Found: C, 71.85; H, 6.06; N, 6.02.

4'-[(3-Butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H,1,2,4-oxadiazen-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid (8d). This compound was obtained as a hygroscopic white solid (82%); mp 65-70°C; nmr (δ, ppm, CD3OD): 0.15 (3H, t, J = 7 Hz), 1.30 (2H, m), 1.52 (2H, m), 2.00-2.60 (4H, m), 2.82 (2H, m), 4.12 (1H, q, J = 7 Hz), 4.75 (1H, d, J = 14 Hz), 5.20 (1H, d, J = 14 Hz), 7.10-7.90 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.5, 22.0, 28.3, 29.5, 29.7, 30.9, 44.1, 75.1, 125.9, 126.1, 127.3, 128.4, 128.5, 128.8, 129.1, 130.7, 131.1, 132.1, 134.9, 140.6, 140.7, 142.6, 155.2, 167.0, 172.9; ms: (M+H)/z = 471.2289 (calcd for C29H31N2O2: 471.2284). [α]D +47° (c = 0.1, chloroform). Chiral hplc analysis (Diacel OD, eluting with 1.0 ml/min of 92:7.1:0.5 hexane : ethanol : methanol : formic acid) showed the enantiomer ratio to be 96:4 (R1 20.6 min to 3.6 (R1 17.5 min). Anal. Calcd for C29H31O2N2: 1.0 H2O : 0.15 C2H2F2O2: C, 69.59; H, 6.41; N, 5.54; F, 1.69. Found: C, 69.94; H, 6.10; N, 5.29; F, 1.90.

4'-[(Oxophenylacetyl)amino][methyl]yl][1,1'-biphenyl]-2-carboxylic acid, t-butyl ester (9). A mixture of 5c (380 mg, 1.6 mmol), biphenyl bromide (6) (600 mg, 2.0 mmol),10 and cesium carbonate (975 mg, 3.0 mmol) in dimethylformamide (5 ml) was stirred at 25°C for 1 h, after which it was poured into brine and extracted with ether. The extract was washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (65 g), eluting with 4:1 hexane : ethyl acetate, to give 9 as an off white solid, 500 mg (75%); mp 63-64°C; nmr (δ, ppm, CDCl3): 1.42 (9H, s), 4.78 (2H, d, J = 7 Hz), 7.38-8.55 (14H, m); 13C nmr (δ, ppm, CDCl3): 27.5, 43.1, 81.2, 127.1, 127.4, 127.6, 128.4, 129.0, 129.6, 130.4, 130.6, 131.1, 132.7, 133.2, 134.3, 136.0, 141.3, 161.6, 167.7, 187.5; ms: (M+H)/z = 414. Anal. Calcd for C26H25NO4: C, 75.16; H, 6.06; N, 3.37. Found: C, 74.97; H, 5.94; N, 3.07.

3-Butyl-1,2,4-oxadiazen-5(4H)-one (10). To a solution of amidoxime (2) (1.0 g, 8.6 mmol)7 and triethylamine (2.8 ml, 20 mmol) in dichloromethane (80 ml) at -50°C under argon was added a solution of bis(trichloromethyl)carbonate (3.0 g, 10 mmol) in dichloromethane (20 ml). The resulting mixture was stirred for 2 h as it was warmed to 25°C, after which it was poured into water. The pH
of the solution was adjusted to about 7.0 by addition of solid sodium bicarbonate, then the mixture was extracted sequentially with dichloromethane and ethyl acetate. The organic extracts were combined, dried, and concentrated to a red oil. The oil was purified by flash chromatography on silica gel (65 g), eluting with 1:1 hexane : ethyl acetate, to give 10 as a clear oil, 780 mg (64%); nmr (δ, ppm, CDCl₃): 0.97 (3H, t, J = 7 Hz), 1.41 (2H, m), 1.70 (2H, m), 2.65 (2H, t, J = 7 Hz); ¹³C nmr (δ, ppm, CDCl₃): 12.8, 21.8, 24.5, 27.2, 159.6, 161.4; ms: (M+NH₄)/z = 160. Anal. Calcd for C₇H₁₀O₂N₂: C, 50.69; H, 7.09; N, 19.71 Found: C, 50.66; H, 7.21; N, 19.84.

4'-[(3-Butyl-5-oxo-1,2,4-oxadiazol-4(5H)-yl)methyl][1,1'-biphenyl]-2-carboxylic acid t-butyl ester (11). A mixture of 10 (750 mg, 5.3 mmol), 6 (2.4 g, 7 mmol), and cesium carbonate (3.25 g, 10 mmol) in dimethylformamide (15 ml) was stirred at 25°C for 17 h, after which it was poured into brine and extracted with ethyl acetate. The extract was dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (300 g), eluting with 3:1 hexane : ethyl acetate, to give 11 as a colorless oil, 1.87 g (87%); nmr (δ, ppm, CDCl₃): 0.95 (3H, t, J = 7 Hz), 1.30 (9H, s), 1.45 (2H, m), 1.70 (2H, m), 2.55 (2H, t, J = 7 Hz), 4.87 (2H, s), 7.30- 7.90 (8H, m); ¹³C nmr (δ, ppm, CDCl₃): 13.3, 21.8, 24.4, 26.2, 27.3, 45.1, 81.0, 126.7, 127.2, 129.1, 130.2, 130.6, 132.5, 132.9, 140.8, 142.1, 150.9, 159.5, 167.3; ms: (M+H)/z = 409. Anal. Calcd for C₂₄H₂₈N₂O₄: C, 70.57; H, 6.91; N, 6.86 Found: C, 70.73; H, 6.91; N, 6.86.

4'-[(1-(Hydroxymino)pentylamino)methyl][1,1'-biphenyl]-2-carboxylic acid t-butyl ester (12). A mixture of 11 (1.25 g, 3.06 mmol), 1N sodium hydroxide solution (6 ml, 6 mmol) and methanol (15 ml) was stirred at 25°C for 16 h, after which additional 1N sodium hydroxide solution (6 ml, 6 mmol) and methanol (15 ml) were added and the mixture was stirred at 50°C for 24 h. The mixture was then poured into brine, the pH was adjusted to about 7 by addition of 1N hydrochloric acid, and the mixture was extracted with ethyl acetate. The extract was dried and concentrated, and the residue was purified by flash chromatography on silica gel (300 g), eluting with ethyl acetate, to give 12 as a viscous oil, 600 mg (51%); nmr (δ, ppm, CDCl₃): 0.82 (3H, t, J = 7 Hz), 1.20 (9H, s), 1.27 (2H, m), 1.50 (2H, m), 2.15 (2H, t, J = 7 Hz), 4.33 (2H, d, J = 7 Hz), 5.60 (1H, t, J = 7 Hz), 7.20-7.80 (8H, m); ¹³C nmr (δ, ppm, CDCl₃): 13.7, 22.4, 27.6, 28.3, 28.5, 45.7, 81.2, 126.3, 127.1, 128.8, 128.9, 130.3, 130.4, 132.6, 138.1, 140.9, 141.5, 167.8; ms: (M+H)/z = 383.2349 (calcd for C₂₄H₂₈N₂O₃: 383.2334). Attempted drying in vacuo at elevated temperatures to remove residual solvents led to sample decomposition.

4'-[(3-Butyl-5,6-dihydro-5-oxo-4H-1,2,4-oxadiazin-4-yl)methyl][1,1'-biphenyl]-2-carboxylic acid t-butyl ester (7a from 12). A mixture of 12 (77 mg, 0.20 mmol), methyl bromoacetate (0.03 ml, 0.32 mmol), and cesium carbonate (162 mg, 0.5 mmol) in dimethylformamide (1 ml) was stirred at 25°C for 3 h, after which it was poured into brine and extracted with ethyl acetate. The extract was dried and concentrated. The residue was filtered through a short pad of silica gel, washing with 1:1 hexane : ethyl acetate, and the filtrate was reactivated to give crude 13 as an oil. The oil was dissolved in dichloromethane (2 ml) and a solution of trimethylaluminum in hexane was added (0.5 ml of 2M solution, 1 mmol). The mixture was stirred at 25°C under argon for 1 h, poured into 1N hydrochloric acid, and extracted with ethyl acetate. The extract was dried and concentrated, the residue was purified by flash chromatography on silica gel (30 g), eluting with 4:1 hexane : ethyl acetate, to give 7a which was identical with material prepared by alkylation of 5a, 12 mg (14%).
4'-[[3-Butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl]methyl][1,1'-biphenyl]-2-carbonitrile (15). A mixture of 5e (390 mg, 1.5 mmol), biphenyl bromide (16) (408 mg, 1.5 mmol), and cesium carbonate (975 mg, 3.0 mmol) in dimethylformamide (5 ml) was stirred at 25°C for 18 h, after which the mixture was poured into water and extracted into ethyl acetate. The extract was dried and concentrated, and the residue was purified by flash chromatography on silica gel (65 g), eluting with 3:1 hexane:ethyl acetate, to give 15 as a viscous oil, 400 mg (60%); nmr (δ, ppm, CDCl3): 0.80 (3H, 1, J = 7 Hz), 1.25 (ZH, m), 1.45 (ZH, m), 2.0-2.40 (4H, m), 2.80 (ZH, m), 4.08 (lH, dd, J = 3 and 7 Hz), 4.70 (IH, d, J = 14 Hz), 5.08 (lH, d, J = 14 Hz), 7.00-7.80 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.5, 22.0, 28.2, 29.4, 29.8, 30.8, 43.8, 74.9, 110.9, 118.4, 127.4, 127.6, 128.3, 128.7, 129.2, 132.8, 134.0, 137.5, 140.6, 144.4, 154.7, 166.9; ms: (M+H)/z = 452.

3-Butyl-6-(2-phenylethyl)-4-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4H-1,2,4-oxadiazin-5(6H)-one (16). A solution of 15 (400 mg, 0.89 mmol) and tributyltin azide (886 mg, 2.7 mmol)17 in o-xylene (0.5 ml) was stirred at 100°C for 18 h. The mixture was then transferred directly to a flash chromatography column containing silica gel (65 g), and was eluted with 60:40:1 hexane:ethyl acetate:acetic acid. Fractions containing the major ultraviolet absorbing product (λ = 254 nm) were combined and concentrated. The residue was repurified by flash chromatography on silica gel (65 g), eluting with a mixture containing 95.2% ethyl acetate, 2.6% pyridine, 0.8% acetic acid, and 1.4% water. Fractions containing the major product were combined, concentrated, and converted to the corresponding potassium salt by dissolving the residue in methanol and adjusting to pH 10.5 by addition of 0.1N potassium carbonate solution. The solution was immediately transferred to a preparative hplc column containing macroreticular polystyrene (Jordi Gel, 30 x 250). The column was eluted first with one liter of water, then with a linear gradient from water to methanol. Fractions containing the major ultraviolet absorbing product (λ = 254 nm) were combined and concentrated in vacuo, and the residue was lyophilized to give 16 as a white powder, 224 mg (45%); nmr (δ, ppm, CDCl3): 0.95 (3H, 1, J = 7 Hz), 1.40 (2H, m), 1.58 (2H, m), 2.10-2.60 (4H, m), 7.00-7.80 (13H, m); 13C nmr (δ, ppm, CDCl3): 13.9, 23.0, 29.3, 30.4, 31.0, 44.9, 76.2, 127.1, 128.1, 129.5, 130.0, 130.8, 131.1, 131.8, 136.1, 142.1, 142.5, 156.8, 162.7, 168.4; ms: (M+K)/z = 533. Anal. Calcd for C29H29N6O2K·1.7 H2O: C, 61.83; H, 5.80; N, 14.92 Found: C, 61.83; H, 5.45; N, 14.64.

ACKNOWLEDGEMENT

We thank Ms. Gabriella Cucinotta and Ms. Sharon Williams for performing radioligand binding assays, Ms. Loryn Williams and Ms. Susan Taylor for chiral hplc analysis, and the Bristol-Myers Squibb Department of Analytical Chemistry for microanalysis and mass spectra.

REFERENCES


Received, 21st October, 1992